NEW YORK (GenomeWeb) – Belgian MDx Firm Biocartis announced today that it has received a €1.4 million ($1.5 million) grant from the Flemish Agency for Innovation by Science and Technology (IWT) to support the development of liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics for melanoma and colorectal cancer.

The funds, made as part of an IWT-subsidized collaboration project called Early Diagnosis by Easy Sampling, will also support more general research on improved liquid biopsy methodologies, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.